trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['enhertu', '$azn']
enhertu shows 37.1% response rate in her2-expressing solid tumours $azn #asco23 
The latest global #pharma news, insights, analysis, and views providing you with an information edge.  FirstWord Pharma. Where people who know first, go first.